Max Healthcare Institute Ltd Q1 FY2025 Concall Summary

Key Takeaways

• Solid quarter, capacity-constrained: Network gross revenue grew 18% YoY and 7% QoQ, but the core story is that Max is running at 77% occupancy, the highest among peers, making brownfield expansion a necessity rather than a choice.
• Margins absorbed multiple headwinds: Operating EBITDA margin landed at 26.5%, pressured by annual merit increases, GST on variable management fees, and a sharp drop in immigration health check footfalls due to visa regulation changes in Canada and the UK.
• Dwarka is live, the pipeline is concrete: The 303-bed Dwarka hospital opened in July, and management expects it to break even within 6 to 9 months. A new built-to-suit 250-bed hospital in Mohali was announced, reinforcing the asset-light strategy.
• ARPOB growth is muted but explainable: ARPOB rose 7% YoY to ₹80,100, held back by a 2-3 percentage point drag from the immigration visa disruption. Management views this as temporary and has a plan to repurpose the space if it does not recover.
• What to watch next quarter: The pace of the Dwarka ramp-up, whether the immigration visa disruption begins to reverse, and any improvement in the institutional bed mix as the seasonally stronger Q2 unfolds.

Brownfield Expansion & New Capacity

• Dwarka operationalized: Max Super Speciality Hospital, Dwarka (303 beds) opened on July 2, 2024 with 94 beds live, 125 doctors and ~480 nurses and support staff. Pre-launch costs of ₹6 crore were absorbed in Q1, and management sees good early traction.
• Break-even timeline: Dwarka is expected to reach EBITDA break-even by Q4 FY25, i.e., within 6 to 9 months of launch.
• Mohali built-to-suit: A 250-bed hospital on a long-term lease extendable up to 50 years, with the developer bearing land and building cost while Max provides medical equipment, a security deposit and loose furniture. Commissioning is expected by FY28.
• Lucknow and Nagpur ramp-up: Both hospitals are at ~60% occupancy, contributing ₹99 crore revenue and ₹18 crore operating EBITDA, reflecting 21% and 64% YoY growth respectively. Annualized EBITDA per bed is ~₹30 lakhs.
• Lucknow expansion: Environmental clearance received for a new 450-bed tower, with investment of ~₹700 crore plus and completion within 24 months. A 140-bed addition and refurbishment is due by end of calendar year.
• Nagpur expansion: ~25 beds being added through internal reconfiguration by Q3 FY25; environmental clearance application filed for 115 additional beds on two floors, with project completion within 24 months of approval.
• Saket Complex projects: Max Smart (375 beds) completion expected by Q1 FY26, site fully mobilized. Max Vikrant Phase I (415 beds) faces some delay from litigation involving DDA and Delhi Government on tree cutting in an eco-sensitive zone, pushing it to a 2027-28 timeline with a possible couple of quarters of delay.
• Other brownfield projects on track: Nanavati Phase I (241 beds) structure is up, completion by end of this fiscal year. Sector 56, Gurgaon Phase I (300 beds) completion by Q2 FY26. Mohali Phase I (155 beds) completion by Q1 FY26.
• Capacity constraint drives strategy: Max operates at 77% occupancy, the highest among peers, limiting volume growth. Management stated that growth in existing hospitals is not a focus but a necessity because they have run out of capacity. Between the next 8 to 20 months, significant new capacity from brownfield expansions will come through.

Soi: "I think growth in our existing hospitals is not a focus, growth in our existing hospitals is a necessity, because we have run out of capacity."

Margin Dynamics & Headwinds

• EBITDA margin at 26.5%: The quarter absorbed annual merit increases, GST on variable management fees, and a drop in immigration health check footfalls. The immigration disruption alone had a couple of percentage points of impact on margins.
• Clinical mix shift: The business mix moved toward higher-end procedures (more robotics, more oncology). These carry lower margins in percentage terms but higher margins in absolute value terms, so EBITDA per bed on existing hospitals increased.
• Immigration health check disruption: Outpatient footfalls from immigration medicals dropped 48% due to visa regulation changes by Canada, the UK and, to a lesser extent, Australia. This OP business does not convert to inpatients, so it does not affect inpatient volumes, but it does pressure margins. The impact from regulations effective January 1 will continue till Q3, with Q4 being the normal quarter.
• ARPOB growth muted: The 7% YoY ARPOB growth to ₹80,100 was held back by a 2-3 percentage point drag from the immigration visa disruption. Management views this as temporary; if it does not recover, the space will be repurposed for more dialysis beds.
• New hospitals ARPOB lower by design: Lucknow, Nagpur and Dwarka have ARPOB of ~₹45,000 versus ~₹80,000 for the network, because they start at a low base. Management expects this to rise to ₹60,000-65,000 in a year's time as oncology and surgical mix improve, but is not chasing Delhi-level ARPOB for these units.

Soi: "You would rather do a 20% margin on a Rs. 10 lakhs surgery than do a 50% margin on a Rs. 2 lakhs surgery, right? So, the percentage is irrelevant."

Asset-Light Strategy & Capital Allocation

• Mohali built-to-suit model: The developer incurs land and building cost; Max provides medical equipment, an interest-bearing security deposit and loose furniture. The lease is extendable up to 50 years, and the building is constructed to Max's specifications.
• ROCE logic: Management explained that the model works because Max's own ROCEs are significantly higher than the cost of capital embedded in the lease, creating a spread that makes the arrangement accretive.
• Developer confidence: The 50-year lease structure requires the developer to be confident that Max will be around and its balance sheet will hold for that duration, a signal of Max's credit standing.
• Lucknow equity infusion: Max is infusing equity into the Lucknow subsidiary to bring down finance costs.
• Nanavati tax repatriation: Once the Nanavati expansion is complete and cumulative profits are made, withdrawal will happen similar to the BLK precedent, likely 1-2 years down the line.
• Tax rate: Expected to be around 22% going forward.

Soi: "The question is how many hospital chains can offer this. Your own ROCEs have to be significantly higher than what you are paying out over there. In our situation, we are able to take up these hospitals because our ROCEs are significantly higher."

Clinical Mix & Payer Dynamics

• Oncology and robotics driving growth: Revenue growth was led by oncology, orthopedics, renal sciences and increased robotic procedures, alongside tariff revisions across self-pay, insurance and institutional segments.
• Lucknow ARPOB levers: Oncology represents less than 2% of Lucknow revenue versus 24-25% for the overall network. Adding oncology and increasing the surgical mix (currently skewed toward medical) will drive ARPOB improvement. A ~58% EBITDA increase was already achieved in the first three months through low-hanging fruit.
• Institutional bed mix: Institutional bed count is stagnant at around 29%, but throughput has increased and ARPOB from PSU beds improved 10% YoY as Max does higher-end work within those beds. Q1 is a seasonally weaker quarter for institutional business; churn typically happens in Q2 and Q4.
• Insurance negotiations: Max is a price taker, not a price maker. Insurance companies base their rates on Max's schedule of charges for cash-paying patients. Management noted that Max's EBITDA per bed is 55% better than the second-best player and ARPOB is 20% better, providing a buffer in negotiations.
• International patient business: Growth in this segment is outstripping other segments, so its share is incrementally rising. Q1 was an aberration due to temporary blips in Bangladesh, Yemen and Somalia.

Soi: "Insurance companies by the end of the day piggyback on what your schedule of charges is, what your rate list is for cash paying patients."

Network & Subsidiary Performance

• Max@Home: Strong growth of 23% YoY and 6% QoQ, with a high rate of repeat transactions.
• Max Lab: Strong growth of 21% YoY and 6% QoQ.
• Outpatient consults slowdown: Growth fell to 4.5% from 13-14% last year, primarily because immigration business footfalls dropped 48%. This OP business does not convert to inpatients, so inpatient volumes are unaffected.
• New markets: Max has added two new cities in the past six months (Lucknow and Nagpur) and intends to go to other high-ROCE, high-opportunity markets beyond the current 20 locations.
• Management bandwidth: No bandwidth issues are expected because 85% of growth is brownfield in existing locations, and only three new locations have been added in 5-6 years.

Soi: "85% of our growth coming through going forward is coming through brownfield. So, it's your existing capacity that you are increasing."

Guidance & Commitments

Key Metrics